Full Press Release Details
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025.
RAPP
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
Key Takeaway: Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
Price reaction · baseline $15.35 (2025-09-04 close) · hit after-hours · 3 other RAPP headline(s) in the window, move may be shared
day 0 close
-6.4%
day 1 · peak
+105%
day 3
+45.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+91%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
RAP-219
Phase 3 · Focal Seizure